BD Diagnostics, Diagenode introduce gastrointestinal tract infections assays in Europe

21 April 2013 (Last Updated April 21st, 2013 18:30)

BD Diagnostics and Diagenode have announced the European launch of their gastrointestinal tract infections assays.

BD Diagnostics and Diagenode have announced the European launch of their gastrointestinal tract infections assays.

The in-vitro diagnostic (IVD) assays include the Diagenode enteric viral panel primers and probes kit, designed for use with the BD MAX RNA3 extraction kit and BD MAX PCR cartridges, and the BD MAX enteric bacterial panel for use on the BD MAX system.

Using stool specimens, the automated enteric viral panel detects norovirus (genogroups I and II) and rotavirus species, while the enteric bacterial panel detects Campylobacter spp. (jejuni and coli), Salmonella spp., Shigellosis disease (Shigella spp. / Enteroinvasive E. coli) as well as Shiga-toxin types 1a and 2a.

"The in-vitro diagnostic (IVD) assays include the Diagenode enteric viral panel primers and probes kit, designed for use with the BD MAX RNA3 extraction kit and BD MAX PCR cartridges, and the BD MAX enteric bacterial panel for use on the BD MAX system."

The new products available on the BD MAX system are also expected to help laboratory technicians to standardise the extraction process and offer improved laboratory workflow.

BD Diagnostics diagnostic systems president Tom Polen said BD's suite of enteric assays on the BD MAX system will allow for targeted testing needs based on patient and clinical presentation, optimising both clinical and economic outcomes.

"The expanding BD MAX system product menu and open system capabilities, full automation and standardized workflow will enable laboratories to consolidate and standardize a broad range of molecular tests to build programs that meet both their current and future clinical needs," Polen added.

In addition, the BD MAX enteric ovum and parasite panel is being developed for the qualitative detection of parasitic enteric pathogens Giardia lamblia,Cryptosporidium spp. (C. hominus and C. parvum) and Entamoeba histolytica directly from stool specimens.

Through internal development and the Diagenode collaboration, BD is also planning to further expand the BD MAX molecular testing menu by launching additional assays throughout 2013.